Literature DB >> 27919055

Associations with health-related quality of life after intracerebral haemorrhage: pooled analysis of INTERACT studies.

Candice Delcourt1,2, Danni Zheng1, Xiaoying Chen1, Maree Hackett1,3, Hisatomi Arima1,4, Jun Hata5, Emma Heeley6, Rustam Al-Shahi Salman7, Mark Woodward1,8, Yining Huang9, Thompson Robinson10, Pablo M Lavados11, Richard I Lindley1,12, Christian Stapf13, Leo Davies1,2, John Chalmers1,2, Craig S Anderson1,2,14, Shoichiro Sato1,15.   

Abstract

BACKGROUND AND
PURPOSE: Limited data exist on health-related quality of life (HRQoL) after intracerebral haemorrhage (ICH). We aimed to determine baseline factors associated with HRQoL among participants of the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trials (INTERACT 1 and 2).
METHODS: The INTERACT studies were randomised controlled trials of early intensive blood pressure (BP) lowering in patients with ICH (<6 hours) and elevated systolic BP (150-220 mm Hg). HRQoL was determined using the European Quality of Life Scale (EQ-5D) at 90 days, completed by patients or proxy responders. Binary logistic regression analyses were performed to identify factors associated with poor overall HRQoL.
RESULTS: 2756 patients were included. Demographic, clinical and radiological factors associated with lower EQ-5D utility score were age, randomisation outside of China, antithrombotic use, high baseline National Institutes of Health Stroke Scale (NIHSS) score, larger ICH, presence of intraventricular extension and use of proxy responders. High (≥14) NIHSS score, larger ICH and proxy responders were associated with low scores in all five dimensions of the EQ-5D. The NIHSS score had a strong association with poor HRQoL (p<0.001). Female gender and antithrombotic use were associated with decreased scores in dimensions of pain/discomfort and usual activity, respectively.
CONCLUSIONS: Poor HRQoL was associated with age, comorbidities, proxy source of assessment, clinical severity and ICH characteristics. The strongest association was with initial clinical severity defined by high NIHSS score. TRIAL REGISTRATION NUMBERS: NCT00226096 and NCT00716079; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27919055     DOI: 10.1136/jnnp-2016-314414

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

1.  Astrocyte heme oxygenase-1 reduces mortality and improves outcome after collagenase-induced intracerebral hemorrhage.

Authors:  Jing Chen-Roetling; Pramod Kamalapathy; Yang Cao; Wei Song; Hyman M Schipper; Raymond F Regan
Journal:  Neurobiol Dis       Date:  2017-03-18       Impact factor: 5.996

2.  Quality of life and depression 3 months after intracerebral hemorrhage.

Authors:  Hanne Sallinen; Tiina Sairanen; Daniel Strbian
Journal:  Brain Behav       Date:  2019-03-24       Impact factor: 2.708

3.  Differences in bleeding patterns and outcome after intracerebral hemorrhage due to vascular malformations.

Authors:  Nazife Dinc; Sae-Yeon Won; Nina Brawanski; Michael Eibach; Johanna Quick-Weller; Jürgen Konczalla; Joachim Berkefeld; Volker Seifert; Gerhard Marquardt
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

4.  Impact of brain atrophy on 90-day functional outcome after moderate-volume basal ganglia hemorrhage.

Authors:  Sae Min Kwon; Kyu-Sun Choi; Hyeong-Joong Yi; Yong Ko; Young-Soo Kim; Koang-Hum Bak; Hyoung-Joon Chun; Young-Jun Lee; Ji Young Lee
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

Review 5.  Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.

Authors:  Jenna E Koschnitzky; Richard F Keep; David D Limbrick; James P McAllister; Jill A Morris; Jennifer Strahle; Yun C Yung
Journal:  Fluids Barriers CNS       Date:  2018-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.